New York · 2025-2026 session
Status: Introduced
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
PRINT NUMBER 9010B (2026-05-04)